solution of 6-ohdahcl (3.0 μg/μl dissolved in saline containing 0.02% ascorbic acid (Millipore)
Millipore is a verified supplier 
90
Structured Review
Millipore
solution of 6-ohdahcl (3.0 μg/μl dissolved in saline containing 0.02% ascorbic acid
Solution Of 6 Ohdahcl (3.0 μg/μl Dissolved In Saline Containing 0.02% Ascorbic Acid, supplied by Millipore, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/saline+solution+with+ascorbic+acid/6+ohda/pm30030752-45-9-24
Average 90 stars, based on 1 article reviews
Solution Of 6 Ohdahcl (3.0 μg/μl Dissolved In Saline Containing 0.02% Ascorbic Acid, supplied by Millipore, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/saline+solution+with+ascorbic+acid/6+ohda/pm30030752-45-9-24
Average 90 stars, based on 1 article reviews
solution of 6-ohdahcl (3.0 μg/μl dissolved in saline containing 0.02% ascorbic acid - by Bioz Stars,
2026-09
90/100 stars
Images
Related Articles
Concentration Assay:Article Title: Abscisic Acid Rescues Behavior in Adult Female Mice in Attention Deficit Disorder with Hyperactivity Model of Dopamine Depletion by Regulating Microglia and Increasing Vesicular GABA Transporter Expression. Article Snippet: At postnatal day 5 (P5), pups of the lesion group received an injection of 6-hydroxydopamine (6-OHDA) ( Article Title: Supporting Information for Ameliorating parkinsonian motor dysfunction by targeting histamine receptors in entopeduncular nucleus–thalamus circuitry Article Snippet: A total volume of 0.5 μl of the Article Title: ATF4 activates a transcriptional program that chronically suppresses mTOR activity promoting neurodegeneration in Parkinson’s disease models Article Snippet: Article Title: Additive neurorestorative effects of exercise and docosahexaenoic acid intake in a mouse model of Parkinson’s disease Article Snippet: Four μg of Article Title: The anti-dyskinetic effect of the clinic-ready mGluR 2 positive allosteric modulator AZD8529 in the 6-OHDA-lesioned rat. Article Snippet: l-3,4-dihydroxyphenylalanine (l-DOPA) remains the main treatment for motor symptoms of Parkinson’s disease (PD).. However, chronic use is associated with the development of complications such as l-DOPA-induced dyskinesia.. We previously demonstrated that LY-487,379, a highly selective metabotropic glutamate receptor 2 (mGluR2) positive allosteric modulator (PAM), reduces the severity of l-DOPA-induced abnormal involuntary movements (AIMs) in the 6-hydroxydopamine (6-OHDA)-lesioned rat model of PD, without interfering with the anti-parkinsonian action of l-DOPA. Article Title: Changes in gene expression of D2 and D5 receptors in the thalamus and midbrain caused by a persistent painful stimulus in Parkinsonian rats. Article Snippet: Pain is the most common and underdiagnosed non-motor symptom in Parkinson’s disease.. Dopaminergic receptors D2 and D5 have been implicated in pain modulation.. In this study, the expression of D2 and D5 receptors in the midbrain and thalamus in response to a painful stimulus was evaluated. Article Title: α-Synuclein targeted therapy with multiple pathological improvement for Parkinson's disease by macrocyclic amphiphile nanomedicine. Article Snippet: The toxic species formed by the pathological aggregation of α-synuclein (α-Syn) is one of the core pathogenic mechanisms in Parkinson’s disease, leading to mitochondrial dysfunction, oxidative stress and ultimately degeneration and loss of dopaminergic neurons.. Developing effective inhibitors targeting α-Syn fibrillization critically requires the simultaneous achievement of (1) strong and selective binding of α-Syn for efficient disintegration of fibrils, as well as (2) robust transmembrane capability for efficient cellular uptake.. Herein, the co-assembly of guanidinium-modified calixarene (GCA) and cyclodextrin (CD), termed GCA-CD, is screened fully accommodating these conditions. Article Title: Supporting Information for Ameliorating parkinsonian motor dysfunction by targeting histamine receptors in entopeduncular nucleus–thalamus circuitry Article Snippet: All 6-OHDA-lesioned mice used in this study were tested for rotational behavior under injection of Saline:Article Title: Abscisic Acid Rescues Behavior in Adult Female Mice in Attention Deficit Disorder with Hyperactivity Model of Dopamine Depletion by Regulating Microglia and Increasing Vesicular GABA Transporter Expression. Article Snippet: At postnatal day 5 (P5), pups of the lesion group received an injection of 6-hydroxydopamine (6-OHDA) ( Article Title: Supporting Information for Ameliorating parkinsonian motor dysfunction by targeting histamine receptors in entopeduncular nucleus–thalamus circuitry Article Snippet: A total volume of 0.5 μl of the Article Title: ATF4 activates a transcriptional program that chronically suppresses mTOR activity promoting neurodegeneration in Parkinson’s disease models Article Snippet: Article Title: Additive neurorestorative effects of exercise and docosahexaenoic acid intake in a mouse model of Parkinson’s disease Article Snippet: Four μg of Article Title: The anti-dyskinetic effect of the clinic-ready mGluR 2 positive allosteric modulator AZD8529 in the 6-OHDA-lesioned rat. Article Snippet: l-3,4-dihydroxyphenylalanine (l-DOPA) remains the main treatment for motor symptoms of Parkinson’s disease (PD).. However, chronic use is associated with the development of complications such as l-DOPA-induced dyskinesia.. We previously demonstrated that LY-487,379, a highly selective metabotropic glutamate receptor 2 (mGluR2) positive allosteric modulator (PAM), reduces the severity of l-DOPA-induced abnormal involuntary movements (AIMs) in the 6-hydroxydopamine (6-OHDA)-lesioned rat model of PD, without interfering with the anti-parkinsonian action of l-DOPA. Article Title: Changes in gene expression of D2 and D5 receptors in the thalamus and midbrain caused by a persistent painful stimulus in Parkinsonian rats. Article Snippet: Pain is the most common and underdiagnosed non-motor symptom in Parkinson’s disease.. Dopaminergic receptors D2 and D5 have been implicated in pain modulation.. In this study, the expression of D2 and D5 receptors in the midbrain and thalamus in response to a painful stimulus was evaluated. Article Title: α-Synuclein targeted therapy with multiple pathological improvement for Parkinson's disease by macrocyclic amphiphile nanomedicine. Article Snippet: The toxic species formed by the pathological aggregation of α-synuclein (α-Syn) is one of the core pathogenic mechanisms in Parkinson’s disease, leading to mitochondrial dysfunction, oxidative stress and ultimately degeneration and loss of dopaminergic neurons.. Developing effective inhibitors targeting α-Syn fibrillization critically requires the simultaneous achievement of (1) strong and selective binding of α-Syn for efficient disintegration of fibrils, as well as (2) robust transmembrane capability for efficient cellular uptake.. Herein, the co-assembly of guanidinium-modified calixarene (GCA) and cyclodextrin (CD), termed GCA-CD, is screened fully accommodating these conditions. Article Title: Supporting Information for Ameliorating parkinsonian motor dysfunction by targeting histamine receptors in entopeduncular nucleus–thalamus circuitry Article Snippet: All 6-OHDA-lesioned mice used in this study were tested for rotational behavior under injection of Injection:Article Title: Abscisic Acid Rescues Behavior in Adult Female Mice in Attention Deficit Disorder with Hyperactivity Model of Dopamine Depletion by Regulating Microglia and Increasing Vesicular GABA Transporter Expression. Article Snippet: At postnatal day 5 (P5), pups of the lesion group received an injection of 6-hydroxydopamine (6-OHDA) ( Article Title: Supporting Information for Ameliorating parkinsonian motor dysfunction by targeting histamine receptors in entopeduncular nucleus–thalamus circuitry Article Snippet: A total volume of 0.5 μl of the Article Title: ATF4 activates a transcriptional program that chronically suppresses mTOR activity promoting neurodegeneration in Parkinson’s disease models Article Snippet: Article Title: Additive neurorestorative effects of exercise and docosahexaenoic acid intake in a mouse model of Parkinson’s disease Article Snippet: Four μg of Article Title: The anti-dyskinetic effect of the clinic-ready mGluR 2 positive allosteric modulator AZD8529 in the 6-OHDA-lesioned rat. Article Snippet: l-3,4-dihydroxyphenylalanine (l-DOPA) remains the main treatment for motor symptoms of Parkinson’s disease (PD).. However, chronic use is associated with the development of complications such as l-DOPA-induced dyskinesia.. We previously demonstrated that LY-487,379, a highly selective metabotropic glutamate receptor 2 (mGluR2) positive allosteric modulator (PAM), reduces the severity of l-DOPA-induced abnormal involuntary movements (AIMs) in the 6-hydroxydopamine (6-OHDA)-lesioned rat model of PD, without interfering with the anti-parkinsonian action of l-DOPA. Article Title: Changes in gene expression of D2 and D5 receptors in the thalamus and midbrain caused by a persistent painful stimulus in Parkinsonian rats. Article Snippet: Pain is the most common and underdiagnosed non-motor symptom in Parkinson’s disease.. Dopaminergic receptors D2 and D5 have been implicated in pain modulation.. In this study, the expression of D2 and D5 receptors in the midbrain and thalamus in response to a painful stimulus was evaluated. Article Title: α-Synuclein targeted therapy with multiple pathological improvement for Parkinson's disease by macrocyclic amphiphile nanomedicine. Article Snippet: The toxic species formed by the pathological aggregation of α-synuclein (α-Syn) is one of the core pathogenic mechanisms in Parkinson’s disease, leading to mitochondrial dysfunction, oxidative stress and ultimately degeneration and loss of dopaminergic neurons.. Developing effective inhibitors targeting α-Syn fibrillization critically requires the simultaneous achievement of (1) strong and selective binding of α-Syn for efficient disintegration of fibrils, as well as (2) robust transmembrane capability for efficient cellular uptake.. Herein, the co-assembly of guanidinium-modified calixarene (GCA) and cyclodextrin (CD), termed GCA-CD, is screened fully accommodating these conditions. Article Title: Supporting Information for Ameliorating parkinsonian motor dysfunction by targeting histamine receptors in entopeduncular nucleus–thalamus circuitry Article Snippet: All 6-OHDA-lesioned mice used in this study were tested for rotational behavior under injection of Control:Article Title: Abscisic Acid Rescues Behavior in Adult Female Mice in Attention Deficit Disorder with Hyperactivity Model of Dopamine Depletion by Regulating Microglia and Increasing Vesicular GABA Transporter Expression. Article Snippet: At postnatal day 5 (P5), pups of the lesion group received an injection of 6-hydroxydopamine (6-OHDA) ( Article Title: Supporting Information for Ameliorating parkinsonian motor dysfunction by targeting histamine receptors in entopeduncular nucleus–thalamus circuitry Article Snippet: A total volume of 0.5 μl of the Article Title: ATF4 activates a transcriptional program that chronically suppresses mTOR activity promoting neurodegeneration in Parkinson’s disease models Article Snippet: Article Title: Additive neurorestorative effects of exercise and docosahexaenoic acid intake in a mouse model of Parkinson’s disease Article Snippet: Four μg of Article Title: The anti-dyskinetic effect of the clinic-ready mGluR 2 positive allosteric modulator AZD8529 in the 6-OHDA-lesioned rat. Article Snippet: l-3,4-dihydroxyphenylalanine (l-DOPA) remains the main treatment for motor symptoms of Parkinson’s disease (PD).. However, chronic use is associated with the development of complications such as l-DOPA-induced dyskinesia.. We previously demonstrated that LY-487,379, a highly selective metabotropic glutamate receptor 2 (mGluR2) positive allosteric modulator (PAM), reduces the severity of l-DOPA-induced abnormal involuntary movements (AIMs) in the 6-hydroxydopamine (6-OHDA)-lesioned rat model of PD, without interfering with the anti-parkinsonian action of l-DOPA. Article Title: Changes in gene expression of D2 and D5 receptors in the thalamus and midbrain caused by a persistent painful stimulus in Parkinsonian rats. Article Snippet: Pain is the most common and underdiagnosed non-motor symptom in Parkinson’s disease.. Dopaminergic receptors D2 and D5 have been implicated in pain modulation.. In this study, the expression of D2 and D5 receptors in the midbrain and thalamus in response to a painful stimulus was evaluated. Article Title: α-Synuclein targeted therapy with multiple pathological improvement for Parkinson's disease by macrocyclic amphiphile nanomedicine. Article Snippet: The toxic species formed by the pathological aggregation of α-synuclein (α-Syn) is one of the core pathogenic mechanisms in Parkinson’s disease, leading to mitochondrial dysfunction, oxidative stress and ultimately degeneration and loss of dopaminergic neurons.. Developing effective inhibitors targeting α-Syn fibrillization critically requires the simultaneous achievement of (1) strong and selective binding of α-Syn for efficient disintegration of fibrils, as well as (2) robust transmembrane capability for efficient cellular uptake.. Herein, the co-assembly of guanidinium-modified calixarene (GCA) and cyclodextrin (CD), termed GCA-CD, is screened fully accommodating these conditions. Article Title: Supporting Information for Ameliorating parkinsonian motor dysfunction by targeting histamine receptors in entopeduncular nucleus–thalamus circuitry Article Snippet: All 6-OHDA-lesioned mice used in this study were tested for rotational behavior under injection of Immunostaining:Article Title: Abscisic Acid Rescues Behavior in Adult Female Mice in Attention Deficit Disorder with Hyperactivity Model of Dopamine Depletion by Regulating Microglia and Increasing Vesicular GABA Transporter Expression. Article Snippet: At postnatal day 5 (P5), pups of the lesion group received an injection of 6-hydroxydopamine (6-OHDA) ( Article Title: Supporting Information for Ameliorating parkinsonian motor dysfunction by targeting histamine receptors in entopeduncular nucleus–thalamus circuitry Article Snippet: A total volume of 0.5 μl of the Article Title: ATF4 activates a transcriptional program that chronically suppresses mTOR activity promoting neurodegeneration in Parkinson’s disease models Article Snippet: Article Title: Additive neurorestorative effects of exercise and docosahexaenoic acid intake in a mouse model of Parkinson’s disease Article Snippet: Four μg of Article Title: The anti-dyskinetic effect of the clinic-ready mGluR 2 positive allosteric modulator AZD8529 in the 6-OHDA-lesioned rat. Article Snippet: l-3,4-dihydroxyphenylalanine (l-DOPA) remains the main treatment for motor symptoms of Parkinson’s disease (PD).. However, chronic use is associated with the development of complications such as l-DOPA-induced dyskinesia.. We previously demonstrated that LY-487,379, a highly selective metabotropic glutamate receptor 2 (mGluR2) positive allosteric modulator (PAM), reduces the severity of l-DOPA-induced abnormal involuntary movements (AIMs) in the 6-hydroxydopamine (6-OHDA)-lesioned rat model of PD, without interfering with the anti-parkinsonian action of l-DOPA. Article Title: Changes in gene expression of D2 and D5 receptors in the thalamus and midbrain caused by a persistent painful stimulus in Parkinsonian rats. Article Snippet: Pain is the most common and underdiagnosed non-motor symptom in Parkinson’s disease.. Dopaminergic receptors D2 and D5 have been implicated in pain modulation.. In this study, the expression of D2 and D5 receptors in the midbrain and thalamus in response to a painful stimulus was evaluated. Article Title: α-Synuclein targeted therapy with multiple pathological improvement for Parkinson's disease by macrocyclic amphiphile nanomedicine. Article Snippet: The toxic species formed by the pathological aggregation of α-synuclein (α-Syn) is one of the core pathogenic mechanisms in Parkinson’s disease, leading to mitochondrial dysfunction, oxidative stress and ultimately degeneration and loss of dopaminergic neurons.. Developing effective inhibitors targeting α-Syn fibrillization critically requires the simultaneous achievement of (1) strong and selective binding of α-Syn for efficient disintegration of fibrils, as well as (2) robust transmembrane capability for efficient cellular uptake.. Herein, the co-assembly of guanidinium-modified calixarene (GCA) and cyclodextrin (CD), termed GCA-CD, is screened fully accommodating these conditions. Article Title: Supporting Information for Ameliorating parkinsonian motor dysfunction by targeting histamine receptors in entopeduncular nucleus–thalamus circuitry Article Snippet: All 6-OHDA-lesioned mice used in this study were tested for rotational behavior under injection of Binding Assay:Article Title: Abscisic Acid Rescues Behavior in Adult Female Mice in Attention Deficit Disorder with Hyperactivity Model of Dopamine Depletion by Regulating Microglia and Increasing Vesicular GABA Transporter Expression. Article Snippet: At postnatal day 5 (P5), pups of the lesion group received an injection of 6-hydroxydopamine (6-OHDA) ( Article Title: Supporting Information for Ameliorating parkinsonian motor dysfunction by targeting histamine receptors in entopeduncular nucleus–thalamus circuitry Article Snippet: A total volume of 0.5 μl of the Article Title: ATF4 activates a transcriptional program that chronically suppresses mTOR activity promoting neurodegeneration in Parkinson’s disease models Article Snippet: Article Title: Additive neurorestorative effects of exercise and docosahexaenoic acid intake in a mouse model of Parkinson’s disease Article Snippet: Four μg of Article Title: The anti-dyskinetic effect of the clinic-ready mGluR 2 positive allosteric modulator AZD8529 in the 6-OHDA-lesioned rat. Article Snippet: l-3,4-dihydroxyphenylalanine (l-DOPA) remains the main treatment for motor symptoms of Parkinson’s disease (PD).. However, chronic use is associated with the development of complications such as l-DOPA-induced dyskinesia.. We previously demonstrated that LY-487,379, a highly selective metabotropic glutamate receptor 2 (mGluR2) positive allosteric modulator (PAM), reduces the severity of l-DOPA-induced abnormal involuntary movements (AIMs) in the 6-hydroxydopamine (6-OHDA)-lesioned rat model of PD, without interfering with the anti-parkinsonian action of l-DOPA. Article Title: Changes in gene expression of D2 and D5 receptors in the thalamus and midbrain caused by a persistent painful stimulus in Parkinsonian rats. Article Snippet: Pain is the most common and underdiagnosed non-motor symptom in Parkinson’s disease.. Dopaminergic receptors D2 and D5 have been implicated in pain modulation.. In this study, the expression of D2 and D5 receptors in the midbrain and thalamus in response to a painful stimulus was evaluated. Article Title: α-Synuclein targeted therapy with multiple pathological improvement for Parkinson's disease by macrocyclic amphiphile nanomedicine. Article Snippet: The toxic species formed by the pathological aggregation of α-synuclein (α-Syn) is one of the core pathogenic mechanisms in Parkinson’s disease, leading to mitochondrial dysfunction, oxidative stress and ultimately degeneration and loss of dopaminergic neurons.. Developing effective inhibitors targeting α-Syn fibrillization critically requires the simultaneous achievement of (1) strong and selective binding of α-Syn for efficient disintegration of fibrils, as well as (2) robust transmembrane capability for efficient cellular uptake.. Herein, the co-assembly of guanidinium-modified calixarene (GCA) and cyclodextrin (CD), termed GCA-CD, is screened fully accommodating these conditions. Article Title: Supporting Information for Ameliorating parkinsonian motor dysfunction by targeting histamine receptors in entopeduncular nucleus–thalamus circuitry Article Snippet: All 6-OHDA-lesioned mice used in this study were tested for rotational behavior under injection of Modification:Article Title: Abscisic Acid Rescues Behavior in Adult Female Mice in Attention Deficit Disorder with Hyperactivity Model of Dopamine Depletion by Regulating Microglia and Increasing Vesicular GABA Transporter Expression. Article Snippet: At postnatal day 5 (P5), pups of the lesion group received an injection of 6-hydroxydopamine (6-OHDA) ( Article Title: Supporting Information for Ameliorating parkinsonian motor dysfunction by targeting histamine receptors in entopeduncular nucleus–thalamus circuitry Article Snippet: A total volume of 0.5 μl of the Article Title: ATF4 activates a transcriptional program that chronically suppresses mTOR activity promoting neurodegeneration in Parkinson’s disease models Article Snippet: Article Title: Additive neurorestorative effects of exercise and docosahexaenoic acid intake in a mouse model of Parkinson’s disease Article Snippet: Four μg of Article Title: The anti-dyskinetic effect of the clinic-ready mGluR 2 positive allosteric modulator AZD8529 in the 6-OHDA-lesioned rat. Article Snippet: l-3,4-dihydroxyphenylalanine (l-DOPA) remains the main treatment for motor symptoms of Parkinson’s disease (PD).. However, chronic use is associated with the development of complications such as l-DOPA-induced dyskinesia.. We previously demonstrated that LY-487,379, a highly selective metabotropic glutamate receptor 2 (mGluR2) positive allosteric modulator (PAM), reduces the severity of l-DOPA-induced abnormal involuntary movements (AIMs) in the 6-hydroxydopamine (6-OHDA)-lesioned rat model of PD, without interfering with the anti-parkinsonian action of l-DOPA. Article Title: Changes in gene expression of D2 and D5 receptors in the thalamus and midbrain caused by a persistent painful stimulus in Parkinsonian rats. Article Snippet: Pain is the most common and underdiagnosed non-motor symptom in Parkinson’s disease.. Dopaminergic receptors D2 and D5 have been implicated in pain modulation.. In this study, the expression of D2 and D5 receptors in the midbrain and thalamus in response to a painful stimulus was evaluated. Article Title: α-Synuclein targeted therapy with multiple pathological improvement for Parkinson's disease by macrocyclic amphiphile nanomedicine. Article Snippet: The toxic species formed by the pathological aggregation of α-synuclein (α-Syn) is one of the core pathogenic mechanisms in Parkinson’s disease, leading to mitochondrial dysfunction, oxidative stress and ultimately degeneration and loss of dopaminergic neurons.. Developing effective inhibitors targeting α-Syn fibrillization critically requires the simultaneous achievement of (1) strong and selective binding of α-Syn for efficient disintegration of fibrils, as well as (2) robust transmembrane capability for efficient cellular uptake.. Herein, the co-assembly of guanidinium-modified calixarene (GCA) and cyclodextrin (CD), termed GCA-CD, is screened fully accommodating these conditions. Article Title: Supporting Information for Ameliorating parkinsonian motor dysfunction by targeting histamine receptors in entopeduncular nucleus–thalamus circuitry Article Snippet: All 6-OHDA-lesioned mice used in this study were tested for rotational behavior under injection of Marker:Article Title: Abscisic Acid Rescues Behavior in Adult Female Mice in Attention Deficit Disorder with Hyperactivity Model of Dopamine Depletion by Regulating Microglia and Increasing Vesicular GABA Transporter Expression. Article Snippet: At postnatal day 5 (P5), pups of the lesion group received an injection of 6-hydroxydopamine (6-OHDA) ( Article Title: Supporting Information for Ameliorating parkinsonian motor dysfunction by targeting histamine receptors in entopeduncular nucleus–thalamus circuitry Article Snippet: A total volume of 0.5 μl of the Article Title: ATF4 activates a transcriptional program that chronically suppresses mTOR activity promoting neurodegeneration in Parkinson’s disease models Article Snippet: Article Title: Additive neurorestorative effects of exercise and docosahexaenoic acid intake in a mouse model of Parkinson’s disease Article Snippet: Four μg of Article Title: The anti-dyskinetic effect of the clinic-ready mGluR 2 positive allosteric modulator AZD8529 in the 6-OHDA-lesioned rat. Article Snippet: l-3,4-dihydroxyphenylalanine (l-DOPA) remains the main treatment for motor symptoms of Parkinson’s disease (PD).. However, chronic use is associated with the development of complications such as l-DOPA-induced dyskinesia.. We previously demonstrated that LY-487,379, a highly selective metabotropic glutamate receptor 2 (mGluR2) positive allosteric modulator (PAM), reduces the severity of l-DOPA-induced abnormal involuntary movements (AIMs) in the 6-hydroxydopamine (6-OHDA)-lesioned rat model of PD, without interfering with the anti-parkinsonian action of l-DOPA. Article Title: Changes in gene expression of D2 and D5 receptors in the thalamus and midbrain caused by a persistent painful stimulus in Parkinsonian rats. Article Snippet: Pain is the most common and underdiagnosed non-motor symptom in Parkinson’s disease.. Dopaminergic receptors D2 and D5 have been implicated in pain modulation.. In this study, the expression of D2 and D5 receptors in the midbrain and thalamus in response to a painful stimulus was evaluated. Article Title: α-Synuclein targeted therapy with multiple pathological improvement for Parkinson's disease by macrocyclic amphiphile nanomedicine. Article Snippet: The toxic species formed by the pathological aggregation of α-synuclein (α-Syn) is one of the core pathogenic mechanisms in Parkinson’s disease, leading to mitochondrial dysfunction, oxidative stress and ultimately degeneration and loss of dopaminergic neurons.. Developing effective inhibitors targeting α-Syn fibrillization critically requires the simultaneous achievement of (1) strong and selective binding of α-Syn for efficient disintegration of fibrils, as well as (2) robust transmembrane capability for efficient cellular uptake.. Herein, the co-assembly of guanidinium-modified calixarene (GCA) and cyclodextrin (CD), termed GCA-CD, is screened fully accommodating these conditions. Article Title: Supporting Information for Ameliorating parkinsonian motor dysfunction by targeting histamine receptors in entopeduncular nucleus–thalamus circuitry Article Snippet: All 6-OHDA-lesioned mice used in this study were tested for rotational behavior under injection of Western Blot:Article Title: Abscisic Acid Rescues Behavior in Adult Female Mice in Attention Deficit Disorder with Hyperactivity Model of Dopamine Depletion by Regulating Microglia and Increasing Vesicular GABA Transporter Expression. Article Snippet: At postnatal day 5 (P5), pups of the lesion group received an injection of 6-hydroxydopamine (6-OHDA) ( Article Title: Supporting Information for Ameliorating parkinsonian motor dysfunction by targeting histamine receptors in entopeduncular nucleus–thalamus circuitry Article Snippet: A total volume of 0.5 μl of the Article Title: ATF4 activates a transcriptional program that chronically suppresses mTOR activity promoting neurodegeneration in Parkinson’s disease models Article Snippet: Article Title: Additive neurorestorative effects of exercise and docosahexaenoic acid intake in a mouse model of Parkinson’s disease Article Snippet: Four μg of Article Title: The anti-dyskinetic effect of the clinic-ready mGluR 2 positive allosteric modulator AZD8529 in the 6-OHDA-lesioned rat. Article Snippet: l-3,4-dihydroxyphenylalanine (l-DOPA) remains the main treatment for motor symptoms of Parkinson’s disease (PD).. However, chronic use is associated with the development of complications such as l-DOPA-induced dyskinesia.. We previously demonstrated that LY-487,379, a highly selective metabotropic glutamate receptor 2 (mGluR2) positive allosteric modulator (PAM), reduces the severity of l-DOPA-induced abnormal involuntary movements (AIMs) in the 6-hydroxydopamine (6-OHDA)-lesioned rat model of PD, without interfering with the anti-parkinsonian action of l-DOPA. Article Title: Changes in gene expression of D2 and D5 receptors in the thalamus and midbrain caused by a persistent painful stimulus in Parkinsonian rats. Article Snippet: Pain is the most common and underdiagnosed non-motor symptom in Parkinson’s disease.. Dopaminergic receptors D2 and D5 have been implicated in pain modulation.. In this study, the expression of D2 and D5 receptors in the midbrain and thalamus in response to a painful stimulus was evaluated. Article Title: α-Synuclein targeted therapy with multiple pathological improvement for Parkinson's disease by macrocyclic amphiphile nanomedicine. Article Snippet: The toxic species formed by the pathological aggregation of α-synuclein (α-Syn) is one of the core pathogenic mechanisms in Parkinson’s disease, leading to mitochondrial dysfunction, oxidative stress and ultimately degeneration and loss of dopaminergic neurons.. Developing effective inhibitors targeting α-Syn fibrillization critically requires the simultaneous achievement of (1) strong and selective binding of α-Syn for efficient disintegration of fibrils, as well as (2) robust transmembrane capability for efficient cellular uptake.. Herein, the co-assembly of guanidinium-modified calixarene (GCA) and cyclodextrin (CD), termed GCA-CD, is screened fully accommodating these conditions. Article Title: Supporting Information for Ameliorating parkinsonian motor dysfunction by targeting histamine receptors in entopeduncular nucleus–thalamus circuitry Article Snippet: All 6-OHDA-lesioned mice used in this study were tested for rotational behavior under injection of Derivative Assay:Article Title: Abscisic Acid Rescues Behavior in Adult Female Mice in Attention Deficit Disorder with Hyperactivity Model of Dopamine Depletion by Regulating Microglia and Increasing Vesicular GABA Transporter Expression. Article Snippet: At postnatal day 5 (P5), pups of the lesion group received an injection of 6-hydroxydopamine (6-OHDA) ( Article Title: Supporting Information for Ameliorating parkinsonian motor dysfunction by targeting histamine receptors in entopeduncular nucleus–thalamus circuitry Article Snippet: A total volume of 0.5 μl of the Article Title: ATF4 activates a transcriptional program that chronically suppresses mTOR activity promoting neurodegeneration in Parkinson’s disease models Article Snippet: Article Title: Additive neurorestorative effects of exercise and docosahexaenoic acid intake in a mouse model of Parkinson’s disease Article Snippet: Four μg of Article Title: The anti-dyskinetic effect of the clinic-ready mGluR 2 positive allosteric modulator AZD8529 in the 6-OHDA-lesioned rat. Article Snippet: l-3,4-dihydroxyphenylalanine (l-DOPA) remains the main treatment for motor symptoms of Parkinson’s disease (PD).. However, chronic use is associated with the development of complications such as l-DOPA-induced dyskinesia.. We previously demonstrated that LY-487,379, a highly selective metabotropic glutamate receptor 2 (mGluR2) positive allosteric modulator (PAM), reduces the severity of l-DOPA-induced abnormal involuntary movements (AIMs) in the 6-hydroxydopamine (6-OHDA)-lesioned rat model of PD, without interfering with the anti-parkinsonian action of l-DOPA. Article Title: Changes in gene expression of D2 and D5 receptors in the thalamus and midbrain caused by a persistent painful stimulus in Parkinsonian rats. Article Snippet: Pain is the most common and underdiagnosed non-motor symptom in Parkinson’s disease.. Dopaminergic receptors D2 and D5 have been implicated in pain modulation.. In this study, the expression of D2 and D5 receptors in the midbrain and thalamus in response to a painful stimulus was evaluated. Article Title: α-Synuclein targeted therapy with multiple pathological improvement for Parkinson's disease by macrocyclic amphiphile nanomedicine. Article Snippet: The toxic species formed by the pathological aggregation of α-synuclein (α-Syn) is one of the core pathogenic mechanisms in Parkinson’s disease, leading to mitochondrial dysfunction, oxidative stress and ultimately degeneration and loss of dopaminergic neurons.. Developing effective inhibitors targeting α-Syn fibrillization critically requires the simultaneous achievement of (1) strong and selective binding of α-Syn for efficient disintegration of fibrils, as well as (2) robust transmembrane capability for efficient cellular uptake.. Herein, the co-assembly of guanidinium-modified calixarene (GCA) and cyclodextrin (CD), termed GCA-CD, is screened fully accommodating these conditions. Article Title: Supporting Information for Ameliorating parkinsonian motor dysfunction by targeting histamine receptors in entopeduncular nucleus–thalamus circuitry Article Snippet: All 6-OHDA-lesioned mice used in this study were tested for rotational behavior under injection of |